Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.05
+1.5%		$1.83
$1.60
▼
$4.94
$117.77M3.281.13 million shs389,794 shs
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.95
$0.95
$2.03
▼
$5.50
$115.60M0.16216,519 shs549 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$7.68
-1.4%		$6.67
$1.85
▼
$8.45
$115.05M0.08479,869 shs160,244 shs
Vermillion, Inc. stock logo
VRML
Vermillion
$0.30
+6.8%		$3.26
$0.35
▼
$5.78
$29.21M3.47440,144 shs24,099 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+3.59%+12.85%-21.71%-26.81%
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00%0.00%+0.11%+0.11%+72.91%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%-0.13%+13.89%+52.15%+148.88%
Vermillion, Inc. stock logo
VRML
Vermillion
0.00%0.00%0.00%0.00%+16.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$2.05
+1.5%		$1.83
$1.60
▼
$4.94
$117.77M3.281.13 million shs389,794 shs
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.95
$0.95
$2.03
▼
$5.50
$115.60M0.16216,519 shs549 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$7.68
-1.4%		$6.67
$1.85
▼
$8.45
$115.05M0.08479,869 shs160,244 shs
Vermillion, Inc. stock logo
VRML
Vermillion
$0.30
+6.8%		$3.26
$0.35
▼
$5.78
$29.21M3.47440,144 shs24,099 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
0.00%+3.59%+12.85%-21.71%-26.81%
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00%0.00%+0.11%+0.11%+72.91%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00%-0.13%+13.89%+52.15%+148.88%
Vermillion, Inc. stock logo
VRML
Vermillion
0.00%0.00%0.00%0.00%+16.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.64
Moderate Buy$9.80378.05% Upside
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.00
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
1.00
SellN/AN/A
Vermillion, Inc. stock logo
VRML
Vermillion
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VRML, CPIX, BDTX, and CO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/13/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
6/24/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/22/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
5/18/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$70M1.68$0.54 per share3.83$1.97 per share1.04
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$1.24B0.09$0.23 per share4.19$6.34 per share0.15
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$44.52M2.58$0.36 per share21.24$1.64 per share4.68
Vermillion, Inc. stock logo
VRML
Vermillion
$4.54M6.43N/AN/A$0.09 per share3.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.75N/AN/AN/AN/A-32.10%-25.21%11/5/2026 (Estimated)
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$79.04M$0.641.49N/AN/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$2.84M-$0.71N/AN/AN/A-34.40%-28.81%-9.25%11/3/2026 (Estimated)
Vermillion, Inc. stock logo
VRML
Vermillion
-$15.24MN/AN/AN/AN/A-307.31%-155.25%-103.47%N/A

Latest VRML, CPIX, BDTX, and CO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.1954-$0.17+$0.0254-$0.17$5.56 millionN/A
8/4/2026Q2 2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$0.13-$0.20-$0.07-$0.29$8.50 million$0.17 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
Global Cord Blood Co. stock logo
CO
Global Cord Blood
$0.088.41%N/A12.50%N/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Vermillion, Inc. stock logo
VRML
Vermillion
N/AN/AN/AN/AN/A

Latest VRML, CPIX, BDTX, and CO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/13/2026
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$1.507/23/20267/31/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
7.28
7.28
Global Cord Blood Co. stock logo
CO
Global Cord Blood
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A
0.96
0.96
Vermillion, Inc. stock logo
VRML
Vermillion
0.20
2.51
2.49

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
Global Cord Blood Co. stock logo
CO
Global Cord Blood
N/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Vermillion, Inc. stock logo
VRML
Vermillion
18.09%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
Global Cord Blood Co. stock logo
CO
Global Cord Blood
0.50%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
42.07%
Vermillion, Inc. stock logo
VRML
Vermillion
4.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9057.45 million52.12 millionOptionable
Global Cord Blood Co. stock logo
CO
Global Cord Blood
1,202121.55 millionN/ANo Data
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.98 million8.68 millionOptionable
Vermillion, Inc. stock logo
VRML
Vermillion
4397.38 millionN/ANot Optionable

Recent News About These Companies

Vermillion authorities investigate car vs building crash
August 10, 2024  |  keloland.comK
Vermillion, SD Hourly Weather Forecast
April 30, 2024  |  wunderground.comW
Vermillion named Tree City USA
April 21, 2024  |  siouxcityjournal.comS
Vermillion girls' basketball rallies to win Class A state title
March 13, 2024  |  siouxcityjournal.comS
Peoria police thwart school shooting; teen could be charged as an adult
February 18, 2024  |  pjstar.comP
2023 HW Vanguard: Dale Vermillion
October 15, 2023  |  housingwire.comH
Goodwill coming to Vermillion
September 17, 2023  |  siouxcityjournal.comS
In Telangana, Vermillion And Saffron Threads Were Used To Lure Women Voters
September 2, 2023  |  outlookindia.comhttps://www.outlookindia.com/national/telangana-rss-offered-vermillion-and-saffron-threads-to-gain-trust-of-women-voters-magazine-301282
Vermillion, SD 10-Day Weather Forecast
July 17, 2023  |  wunderground.comW
A cold case without a crime: Inside the messy investigation into two missing SD teens in 1971
June 21, 2023  |  grandforksherald.comG
Camellia Vermillion
June 16, 2023  |  health.usnews.comhttps://health.usnews.com/nurse-practitioners/camellia-vermillion-2017770
Dr. Richard L. Knutson
June 6, 2023  |  health.usnews.comhttps://health.usnews.com/dentists/richard-knutson-1784514
Vermillion Elementary School
May 24, 2023  |  usnews.comhttps://www.usnews.com/education/k12/kansas/vermillion-elementary-school-224797
Dr. Kenneth J. Vermillion
May 20, 2023  |  health.usnews.comhttps://health.usnews.com/dentists/kenneth-vermillion-1621386
Golf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain Talk
May 13, 2023  |  news.google.comN
Driver killed after veering into path of dump truck on Highway 52 - Bring Me The News
May 13, 2023  |  news.google.comN
Fatal crash in Vermillion Township closes portion of Highway 52 - CBS News
May 13, 2023  |  news.google.comN
Vermillion, KS Weather Conditions
May 13, 2023  |  wunderground.comW
Vermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain Talk
May 13, 2023  |  news.google.comN
Baseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain Talk
May 13, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
A semi-truck hauls a large cylindrical industrial component past police cars on a nighttime industrial roadway.
These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
By Nathan Reiff | July 28, 2026
Glowing fiber optic cables connected to a data center network switch.
AI Cold War Catches Light: Federal Friction in the Server Rack
By Jeffrey Neal Johnson | August 9, 2026
Rio Tinto logo displayed over a mining site with excavators and a haul truck at sunset.
Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
By Chris Markoch | August 2, 2026
Microsoft logo on a glass office building at dusk, reflecting tech sector sentiment and MSFT stock focus.
No Hangover: Revisiting Microsoft One Week After Earnings
By Chris Markoch | August 7, 2026
Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$2.05 +0.03 (+1.49%)
As of 04:00 PM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Global Cord Blood stock logo

Global Cord Blood NYSE:CO

$0.95 0.00 (0.00%)
As of 08/14/2026

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants. Global Cord Blood was founded on January 17, 2008 and is headquartered in Hong Kong.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$7.68 -0.11 (-1.41%)
As of 04:00 PM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Vermillion stock logo

Vermillion NASDAQ:VRML

Vermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas